New pill shows promise for rare lung cancer mutation in early trial

NCT ID NCT04858958

Completed Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if the drug shrinks tumors and to check its safety at two different daily doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Furmonertinib mesilate (a targeted cancer pill)
What this could lead to: If it works, this could offer a new oral treatment option for people with a hard-to-treat form of lung cancer that has few targeted therapies.
What could go wrong: This is a very early, small Phase 1b study with only 30 participants. It is designed to test safety and dosing, not to prove effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Shanghai Chest hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.